Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 37

1.

Soluble tau aggregates inhibit synaptic long-term depression and amyloid β-facilitated LTD in vivo.

Ondrejcak T, Hu NW, Qi Y, Klyubin I, Corbett GT, Fraser G, Perkinton MS, Walsh DM, Billinton A, Rowan MJ.

Neurobiol Dis. 2019 Jul;127:582-590. doi: 10.1016/j.nbd.2019.03.022. Epub 2019 Mar 22.

PMID:
30910746
2.

Cellular Prion Protein Mediates the Disruption of Hippocampal Synaptic Plasticity by Soluble Tau In Vivo.

Ondrejcak T, Klyubin I, Corbett GT, Fraser G, Hong W, Mably AJ, Gardener M, Hammersley J, Perkinton MS, Billinton A, Walsh DM, Rowan MJ.

J Neurosci. 2018 Dec 12;38(50):10595-10606. doi: 10.1523/JNEUROSCI.1700-18.2018. Epub 2018 Oct 24.

3.

Extracellular Forms of Aβ and Tau from iPSC Models of Alzheimer's Disease Disrupt Synaptic Plasticity.

Hu NW, Corbett GT, Moore S, Klyubin I, O'Malley TT, Walsh DM, Livesey FJ, Rowan MJ.

Cell Rep. 2018 May 15;23(7):1932-1938. doi: 10.1016/j.celrep.2018.04.040.

4.

NLRP3-dependent synaptic plasticity deficit in an Alzheimer's disease amyloidosis model in vivo.

Qi Y, Klyubin I, Cuello AC, Rowan MJ.

Neurobiol Dis. 2018 Jun;114:24-30. doi: 10.1016/j.nbd.2018.02.016. Epub 2018 Feb 23.

PMID:
29477641
5.

Targeting glutamatergic and cellular prion protein mechanisms of amyloid β-mediated persistent synaptic plasticity disruption: Longitudinal studies.

Zhang D, Qi Y, Klyubin I, Ondrejcak T, Sarell CJ, Cuello AC, Collinge J, Rowan MJ.

Neuropharmacology. 2017 Jul 15;121:231-246. doi: 10.1016/j.neuropharm.2017.03.036. Epub 2017 Apr 5.

PMID:
28390893
6.

Amyloid Oligomers and Mature Fibrils Prepared from an Innocuous Protein Cause Diverging Cellular Death Mechanisms.

Harte NP, Klyubin I, McCarthy EK, Min S, Garrahy SA, Xie Y, Davey GP, Boland JJ, Rowan MJ, Mok KH.

J Biol Chem. 2015 Nov 20;290(47):28343-52. doi: 10.1074/jbc.M115.676072. Epub 2015 Jul 28.

7.

Longitudinal testing of hippocampal plasticity reveals the onset and maintenance of endogenous human Aß-induced synaptic dysfunction in individual freely behaving pre-plaque transgenic rats: rapid reversal by anti-Aß agents.

Qi Y, Klyubin I, Harney SC, Hu N, Cullen WK, Grant MK, Steffen J, Wilson EN, Do Carmo S, Remy S, Fuhrmann M, Ashe KH, Cuello AC, Rowan MJ.

Acta Neuropathol Commun. 2014 Dec 24;2:175. doi: 10.1186/s40478-014-0175-x.

8.

Secreted amyloid β-proteins in a cell culture model include N-terminally extended peptides that impair synaptic plasticity.

Welzel AT, Maggio JE, Shankar GM, Walker DE, Ostaszewski BL, Li S, Klyubin I, Rowan MJ, Seubert P, Walsh DM, Selkoe DJ.

Biochemistry. 2014 Jun 24;53(24):3908-21.

9.

Peripheral administration of a humanized anti-PrP antibody blocks Alzheimer's disease Aβ synaptotoxicity.

Klyubin I, Nicoll AJ, Khalili-Shirazi A, Farmer M, Canning S, Mably A, Linehan J, Brown A, Wakeling M, Brandner S, Walsh DM, Rowan MJ, Collinge J.

J Neurosci. 2014 Apr 30;34(18):6140-5. doi: 10.1523/JNEUROSCI.3526-13.2014.

10.

Neurotransmitter receptor and time dependence of the synaptic plasticity disrupting actions of Alzheimer's disease Aβ in vivo.

Klyubin I, Ondrejcak T, Hayes J, Cullen WK, Mably AJ, Walsh DM, Rowan MJ.

Philos Trans R Soc Lond B Biol Sci. 2013 Dec 2;369(1633):20130147. doi: 10.1098/rstb.2013.0147. Print 2014 Jan 5.

11.

Exosomes neutralize synaptic-plasticity-disrupting activity of Aβ assemblies in vivo.

An K, Klyubin I, Kim Y, Jung JH, Mably AJ, O'Dowd ST, Lynch T, Kanmert D, Lemere CA, Finan GM, Park JW, Kim TW, Walsh DM, Rowan MJ, Kim JH.

Mol Brain. 2013 Nov 13;6:47. doi: 10.1186/1756-6606-6-47.

12.

Alzheimer's disease Aβ assemblies mediating rapid disruption of synaptic plasticity and memory.

Klyubin I, Cullen WK, Hu NW, Rowan MJ.

Mol Brain. 2012 Jul 17;5:25. doi: 10.1186/1756-6606-5-25. Review.

13.

A monoclonal antibody against synthetic Aβ dimer assemblies neutralizes brain-derived synaptic plasticity-disrupting Aβ.

O'Nuallain B, Klyubin I, Mc Donald JM, Foster JS, Welzel A, Barry A, Dykoski RK, Cleary JP, Gebbink MF, Rowan MJ, Walsh DM.

J Neurochem. 2011 Oct;119(1):189-201. doi: 10.1111/j.1471-4159.2011.07389.x. Epub 2011 Aug 22.

14.

Interaction between prion protein and toxic amyloid β assemblies can be therapeutically targeted at multiple sites.

Freir DB, Nicoll AJ, Klyubin I, Panico S, Mc Donald JM, Risse E, Asante EA, Farrow MA, Sessions RB, Saibil HR, Clarke AR, Rowan MJ, Walsh DM, Collinge J.

Nat Commun. 2011 Jun 7;2:336. doi: 10.1038/ncomms1341.

15.

Alzheimer's disease brain-derived amyloid-β-mediated inhibition of LTP in vivo is prevented by immunotargeting cellular prion protein.

Barry AE, Klyubin I, Mc Donald JM, Mably AJ, Farrell MA, Scott M, Walsh DM, Rowan MJ.

J Neurosci. 2011 May 18;31(20):7259-63. doi: 10.1523/JNEUROSCI.6500-10.2011.

16.

GluN2B subunit-containing NMDA receptor antagonists prevent Abeta-mediated synaptic plasticity disruption in vivo.

Hu NW, Klyubin I, Anwyl R, Rowan MJ.

Proc Natl Acad Sci U S A. 2009 Dec 1;106(48):20504-9. doi: 10.1073/pnas.0908083106. Epub 2009 Nov 16. Erratum in: Proc Natl Acad Sci U S A. 2010 Jul 13;107(28):12734. Anwy, Roger [corrected to Anwyl, Roger].

17.

Inherent anti-amyloidogenic activity of human immunoglobulin gamma heavy chains.

Adekar SP, Klyubin I, Macy S, Rowan MJ, Solomon A, Dessain SK, O'Nuallain B.

J Biol Chem. 2010 Jan 8;285(2):1066-74. doi: 10.1074/jbc.M109.044321. Epub 2009 Nov 4.

18.

Alzheimer's disease amyloid beta-protein and synaptic function.

Ondrejcak T, Klyubin I, Hu NW, Barry AE, Cullen WK, Rowan MJ.

Neuromolecular Med. 2010 Mar;12(1):13-26. doi: 10.1007/s12017-009-8091-0. Epub 2009 Sep 16. Review.

PMID:
19757208
19.

Persistent inhibition of hippocampal long-term potentiation in vivo by learned helplessness stress.

Ryan BK, Vollmayr B, Klyubin I, Gass P, Rowan MJ.

Hippocampus. 2010 Jun;20(6):758-67. doi: 10.1002/hipo.20677.

PMID:
19623539
20.

Protection against Aβ-mediated rapid disruption of synaptic plasticity and memory by memantine.

Klyubin I, Wang Q, Reed MN, Irving EA, Upton N, Hofmeister J, Cleary JP, Anwyl R, Rowan MJ.

Neurobiol Aging. 2011 Apr;32(4):614-23. doi: 10.1016/j.neurobiolaging.2009.04.005. Epub 2009 May 14.

PMID:
19446369
21.

Amyloid beta protein dimer-containing human CSF disrupts synaptic plasticity: prevention by systemic passive immunization.

Klyubin I, Betts V, Welzel AT, Blennow K, Zetterberg H, Wallin A, Lemere CA, Cullen WK, Peng Y, Wisniewski T, Selkoe DJ, Anwyl R, Walsh DM, Rowan MJ.

J Neurosci. 2008 Apr 16;28(16):4231-7. doi: 10.1523/JNEUROSCI.5161-07.2008.

22.

Synaptic memory mechanisms: Alzheimer's disease amyloid beta-peptide-induced dysfunction.

Rowan MJ, Klyubin I, Wang Q, Hu NW, Anwyl R.

Biochem Soc Trans. 2007 Nov;35(Pt 5):1219-23. Review.

PMID:
17956317
23.

Alpha v integrins mediate beta-amyloid induced inhibition of long-term potentiation.

Wang Q, Klyubin I, Wright S, Griswold-Prenner I, Rowan MJ, Anwyl R.

Neurobiol Aging. 2008 Oct;29(10):1485-93. Epub 2007 Apr 17.

PMID:
17442458
24.

The role of cell-derived oligomers of Abeta in Alzheimer's disease and avenues for therapeutic intervention.

Walsh DM, Klyubin I, Shankar GM, Townsend M, Fadeeva JV, Betts V, Podlisny MB, Cleary JP, Ashe KH, Rowan MJ, Selkoe DJ.

Biochem Soc Trans. 2005 Nov;33(Pt 5):1087-90. Review.

PMID:
16246051
25.

Synaptic plasticity disruption by amyloid beta protein: modulation by potential Alzheimer's disease modifying therapies.

Rowan MJ, Klyubin I, Wang Q, Anwyl R.

Biochem Soc Trans. 2005 Aug;33(Pt 4):563-7. Review.

PMID:
16042545
26.

Amyloid beta protein immunotherapy neutralizes Abeta oligomers that disrupt synaptic plasticity in vivo.

Klyubin I, Walsh DM, Lemere CA, Cullen WK, Shankar GM, Betts V, Spooner ET, Jiang L, Anwyl R, Selkoe DJ, Rowan MJ.

Nat Med. 2005 May;11(5):556-61. Epub 2005 Apr 17.

PMID:
15834427
27.

Mechanisms of the inhibitory effects of amyloid beta-protein on synaptic plasticity.

Rowan MJ, Klyubin I, Wang Q, Anwyl R.

Exp Gerontol. 2004 Nov-Dec;39(11-12):1661-7.

PMID:
15582282
28.

Soluble Arctic amyloid beta protein inhibits hippocampal long-term potentiation in vivo.

Klyubin I, Walsh DM, Cullen WK, Fadeeva JV, Anwyl R, Selkoe DJ, Rowan MJ.

Eur J Neurosci. 2004 May;19(10):2839-46.

PMID:
15147317
29.

Synaptic plasticity in animal models of early Alzheimer's disease.

Rowan MJ, Klyubin I, Cullen WK, Anwyl R.

Philos Trans R Soc Lond B Biol Sci. 2003 Apr 29;358(1432):821-8. Review.

30.

Amyloid-beta oligomers: their production, toxicity and therapeutic inhibition.

Walsh DM, Klyubin I, Fadeeva JV, Rowan MJ, Selkoe DJ.

Biochem Soc Trans. 2002 Aug;30(4):552-7. Review.

PMID:
12196135
31.

Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo.

Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, Rowan MJ, Selkoe DJ.

Nature. 2002 Apr 4;416(6880):535-9.

PMID:
11932745
32.

The role of reactive oxygen species in membrane potential changes in macrophages and astrocytes.

Klyubin IV, Kirpichnikova KM, Ischenko AM, Zhakhov AV, Gamaley IA.

Membr Cell Biol. 2000;13(4):557-66.

PMID:
10926373
33.

Cell-cycle-dependent changes in membrane potential of L-929 cells caused by the effect of hydrogen peroxide.

Gamaley IA, Kirpichnikova KM, Artzybasheva IV, Klyubin IV.

Pflugers Arch. 1999 Jun;438(1):113-5.

PMID:
10370095
34.

Roles of reactive oxygen species: signaling and regulation of cellular functions.

Gamaley IA, Klyubin IV.

Int Rev Cytol. 1999;188:203-55. Review.

PMID:
10208013
35.

Superoxide release is involved in membrane potential changes in mouse peritoneal macrophages.

Gamaley IA, Kirpichnikova KM, Klyubin IV.

Free Radic Biol Med. 1998 Jan 1;24(1):168-74.

PMID:
9436627
36.

Hydrogen peroxide-induced chemotaxis of mouse peritoneal neutrophils.

Klyubin IV, Kirpichnikova KM, Gamaley IA.

Eur J Cell Biol. 1996 Aug;70(4):347-51.

PMID:
8864663
37.

Activation of murine macrophages by hydrogen peroxide.

Gamaley IA, Kirpichnikova KM, Klyubin IV.

Cell Signal. 1994 Nov;6(8):949-57.

PMID:
7718414

Supplemental Content

Loading ...
Support Center